Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients ; volume:6 ; number:1 ; day:3 ; month:10 ; year:2018 ; pages:1-12 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (3.10.2018), 1-12, 12.2018
- Urheber
-
Zhao, Bin
- Beteiligte Personen und Organisationen
-
Zhao, Hong
Zhao, Jiaxin
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0421-z
- URN
-
urn:nbn:de:101:1-2018111223564316840932
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhao, Bin
- Zhao, Hong
- Zhao, Jiaxin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events
Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database
Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials
Clinical Trials Facing “Serious Adverse Events” during the Ongoing COVID-19 Pandemic
Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
“Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic
Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement
Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events
Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database
Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials
Clinical Trials Facing “Serious Adverse Events” during the Ongoing COVID-19 Pandemic
Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
“Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic
Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement
Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events
Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database
Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
Modeling an IT Support for Handling Serious Adverse Events in Clinical Trials
Clinical Trials Facing “Serious Adverse Events” during the Ongoing COVID-19 Pandemic
Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
“Serious Adverse Events” Faced by Clinical Trials: Impact of the COVID-19 Pandemic
Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement